Status: Recruiting
A Study to Find a Suitable Dose of Exl-111 for Further Research
This is a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose trial of Exl-111 in healthy participants. The trials consists of 2 parts, as follows: Part A (SAD): Up to 5 dose cohorts, each with 8 participants, randomized into 2 arms: Exl-111 and placebo. Part B (MAD): Up to 3 dose cohorts, each with 10 participants, randomized into 3 arms: Exl-111, placebo, and an active comparator (omalizumab).
Participants needed: 70
Trial details
Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: Excellergy Inc.Updated: Feb 19, 2026Locations: 1
Eligibility criteria
Healthy, male and female participants 18-55 years of age at Screening [+5]
Received Exl-111 in a prior cohort in this trial [+27]